6-[azabicyclo[4,3,0]nonan-4-yl]-indole | 321744-87-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 6-[azabicyclo[4,3,0]nonan-4-yl]-indole
• 英文别名: 6-[1-Azabicyclo[4.3.0]nonan-4-yl]-indole；6-(1,2,3,5,6,7,8,8a-octahydroindolizin-7-yl)-1H-indole
• CAS: 321744-87-0
• 化学式: C₁₆H₂₀N₂
• 分子量: 240.348
• InChiKey: AGORWRNIXBFPLK-UHFFFAOYSA-N

物化性质

• 沸点：
  417.3±38.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  19
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-萘磺酰氯 、 6-[azabicyclo[4,3,0]nonan-4-yl]-indole 在 sodium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 生成 6-(octahydroindolizin-7-yl)-1-naphthylsulfonyl-indole
  参考文献：
  名称：

  6-Bicyclopiperazinyl-1-arylsulfonylindoles和6-bicyclopiperidinyl-1-arylsulfonylindoles衍生物是新型，有效和选择性的5-HT6受体拮抗剂。

  摘要：

  合成了一系列新的6-双环哌嗪基-1-芳基磺酰基林多斯和6-双环哌啶基-1-芳基磺酰基林多斯衍生物，发现它们是有效的和选择性的5-HT6受体拮抗剂。

  DOI：

  10.1016/s0960-894x(00)00320-6
• 作为产物：
  描述：

  6-溴吲哚 在 叔丁基锂 、 potassium hydride 、 三氟乙酸 作用下， 以 四氢呋喃 为溶剂， 生成 6-[azabicyclo[4,3,0]nonan-4-yl]-indole
  参考文献：
  名称：

  6-Bicyclopiperazinyl-1-arylsulfonylindoles和6-bicyclopiperidinyl-1-arylsulfonylindoles衍生物是新型，有效和选择性的5-HT6受体拮抗剂。

  摘要：

  合成了一系列新的6-双环哌嗪基-1-芳基磺酰基林多斯和6-双环哌啶基-1-芳基磺酰基林多斯衍生物，发现它们是有效的和选择性的5-HT6受体拮抗剂。

  DOI：

  10.1016/s0960-894x(00)00320-6

文献信息

• Heterocyclic compounds for the treatment of migraine
  申请人：NPS Allelix Biopharmaceuticals, Inc.

  公开号：US06716837B1

  公开（公告）日：2004-04-06

  Described herein are compounds useful in the treatment of migraine, which have the general formula: wherein: W is a CH group or a N atom; Z is N or C—R4; B and D are selected independently from CH and N, with the proviso that at least one of B and D is CH and with the further proviso that one of B and D can represent N only when W and Z are both other than N; A is a group of Formula II, III or IV, such that group A contains at least 1 N atom; NR7 is either —NH— or —N═; is a single or double bond; X is a N atom, a CH group or a C(OH) group when is a single bond; or, when is a double bond, a C atom; Y is an NH, N-alkyl, N-benzyl or CH2 group; U and V each represent a N atom or a CH group, with the proviso that both cannot be N; a and b are, independently, 0 or 1; c is an integer from 0 to 3; d is an integer from 1 to 3; e is an integer from 1 to 2; f is an integer from 0 to 3; g is an integer from 3 to 6 and h is an integer from 2 to 3; such that the sum of c and d is at least 2 and the sum of e and f is at least 2; and salts and solvates thereof.

  本文描述了在治疗偏头痛中有用的化合物，其具有以下一般公式：其中：W是一个CH基团或一个N原子；Z是N或C—R4；B和D分别从CH和N中选择，但至少其中一个是CH，并进一步规定其中一个可以表示N，只有当W和Z都不是N时；A是公式II、III或IV的一个基团，使得基团A至少含有1个N原子；NR7要么是—NH—要么是—N═; 是一个单键或双键；X是一个N原子、一个CH基团或一个C(OH)基团，当 是一个单键时；或者，当 是一个双键时，是一个C原子；Y是一个NH、N-烷基、N-苄基或CH2基团；U和V分别代表一个N原子或一个CH基团，但两者不能都是N；a和b分别独立地为0或1；c是一个从0到3的整数；d是一个从1到3的整数；e是一个从1到2的整数；f是一个从0到3的整数；g是一个从3到6的整数，h是一个从2到3的整数；使得c和d的总和至少为2，e和f的总和至少为2；以及它们的盐和溶剂化合物。
• INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE
  申请人：NPS Allelix Corp.

  公开号：EP1196380A2

  公开（公告）日：2002-04-17
• US6716837B1
  申请人：——

  公开号：US6716837B1

  公开（公告）日：2004-04-06
• [EN] HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MIGRAINE<br/>[FR] COMPOSES HETEROCYCLIQUES DESTINES AU TRAITEMENT DE LA MIGRAINE
  申请人：NPS ALLELIX CORP

  公开号：WO2001005758A2

  公开（公告）日：2001-01-25

  Described herein are compounds useful in the treatment of migraine, which have general formulae (I), (II), (III) and (IV), wherein : W is a CH group or an N atom ;Z is N or C-R4; B and D are selected independently from CH and N, with the proviso that at least one of B and D is CH and with the further proviso that one of B and D can represent N only when W and Z are both other than N; A is a group of Formula (II), (III) or (IV), such that group A contains at least 1 N atom ; NR7 is either -NH- or -N=--- is a single or double bond ; X is an N atom, a CH group or a C(OH) group when --- is a single bond; or, when --- is a double bond, a C atom; Y is an NH, N-alkyl, N-benzyl or CH2 group; U and V each represent an N atom or a CH group, with the proviso that both cannot be N; a and b are, independently, 0 or 1; c is an integer from 0 to 3; d is an integer from 1 to 3; e is an integer from 1 to 2; f is an integer from 0 to 3; g is an integer from 3 to 6 and h is an integer from 2 to 3; such that the sum of c and d is at least 2 and the sum of e and f is at least 2; R1 is selected from the group consisting of H, alkyl, alkyloxy, alkanoyl, aminoalkylenyl, alkylaminoalkylenyl, a hydroxyalkylenyl group, an alkyloxyalkylenyl group, a cycloalkyl group, a cycloalkylalkylenyl group, a heterocycloalkyl group, a heterocycloalkylalkylenyl group, an aryl group, a heterocycloaryl group, an amido group, a thioamido group, an arylcarbonyl group and an arylsulfonyl group; R2 and R3 are independently selected from the group consisting of H, alkyl, cycloalkyl, alkenyl and optionally-substituted benzyl; or R2 and R3, together with the nitrogen atom to which they are attached, may form a mono- or bi-cyclic group containing up to 10 carbon atoms and which, in addition, may contain a second heteroatom selected from the group consisting of N, S and O, and which may contain one or more substituents selected from the group consisting of alkyl, hydroxy, hydroxymethyl, alkyloxymethyl, amino and substituted amino; R4 is selected from the group consisting of H, alkyl and cycloalkyl; CR5 represents a group selected from -CH2-, CH(OH)-, -C(O)-, -CH(alkyl)- and -CH(alkyloxy)-; R6 is selected from the group consisting of H, alkyl, aryl, halogen, hydroxy, alkyloxy, amino, monoalkylamino and di-substituted alkylamino; and salts and solvates thereof.
• 6-bicyclopiperazinyl-1-arylsulfonylindoles and 6-bicyclopiperidinyl-1-arylsulfonylindoles derivatives as novel, potent, and selective 5-HT6 receptor antagonists
  作者：Methvin Isaac、Abdelmalik Slassi、Tao Xin、Neil MacLean、Julie Wilson、Kirk McCallum、Hong Wang、Lidia Demchyshyn

  DOI：10.1016/s0960-894x(00)00320-6

  日期：2000.8

  A novel series of 6-bicyclopiperazinyl-1-arylsulfonylindoles and 6-bicyclopiperidinyl-1-arylsulfonylindoles derivatives was synthesized and found to be potent and selective 5-HT6 receptor antagonists.

  合成了一系列新的6-双环哌嗪基-1-芳基磺酰基林多斯和6-双环哌啶基-1-芳基磺酰基林多斯衍生物，发现它们是有效的和选择性的5-HT6受体拮抗剂。